Faldaprevir for the treatment of genotype-1 hepatitis C virus

References

• Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341(8):556-62
   PubMed Web of Science ®Google Scholar
• Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004;44(1):20-9
   PubMed Web of Science ®Google Scholar
• Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999;29(4):1311-16
   PubMed Web of Science ®Google Scholar
• Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012;26(4):401-12
   PubMed Web of Science ®Google Scholar
• Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142(2):105-14
   PubMed Web of Science ®Google Scholar
• Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131(3):174-81
   PubMed Web of Science ®Google Scholar
• Maylin S, Martinot-Peignoux M, Ripault MP, et al. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int 2009;29(4):511-17
   PubMed Web of Science ®Google Scholar
• Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144(7):1450-5; e2
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364(25):2417-28
   PubMed Web of Science ®Google Scholar
• Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with hcv genotype 1 infection and cirrhosis. Gastroenterology 2014;147(1):132-42
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368(20):1878-87
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370(16):1483-93
   PubMed Web of Science ®Google Scholar
• Feld JJ. Interferon-free strategies with a nucleoside/nucleotide analogue. Semin Liver Dis 2014;34(1):37-46
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370(21):1973-82
   PubMed Web of Science ®Google Scholar
• Morano JP, Gibson BA, Altice FL. The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban setting. PLoS ONE 2013;8(5):e64321
   PubMed Web of Science ®Google Scholar
• Andreoni M, Giacometti A, Maida I, et al. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci 2012;16(11):1473-83
   PubMed Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. Aids 2008;22(15):1979-91
   PubMed Web of Science ®Google Scholar
• Pialoux G. [Efficacy of peginterferon plus ribavirin for HIV-HCV co-infection. Results of the APRICOT study]. Presse medicale 2005;34(20 Pt 2):1589-91
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Slim J, Bhatti L, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials 2012;13(3):142-52
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Rodriguez-Torres M, Lalezari JP, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Paper presented at: the 64th Annual Meeting of the American Association for the Study of Liver Diseases. November 1–5; Washington, DC; 2013
   Google Scholar
• Agarwal K, Barnabas A. Treatment of chronic hepatitis C virus infection after liver transplantation. Dig Liver Dis 2013;45(Suppl 5):S349-54
   PubMedGoogle Scholar
• Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014;60(1):78-86
   PubMed Web of Science ®Google Scholar
• Curry MP, Forns X, Chung RT, et al. Sofosbuvir and Ribavirin Prevent Recurrence ofHCV Infection after Liver Transplantation: An Open-Label Study. Gastroenterology 2014;148(1):100-7
   PubMed Web of Science ®Google Scholar
• Bahadi A, Maoujoud O, Zejjari Y, et al. Diagnosis and evaluation of hepatitis C virus among haemodialysis patients. East Mediterr Health J 2013;19(2):192-9
   PubMed Web of Science ®Google Scholar
• Patel PR, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of bloodstream infections in hemodialysis patients. Am J Kidney Dis 2010;56(3):566-77
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Messa P, Martin P. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Med Virol 2010;82(5):768-75
   PubMed Web of Science ®Google Scholar
• White PW, Llinas-Brunet M, Amad M, et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 2010;54(11):4611-18
   PubMed Web of Science ®Google Scholar
• Manns MP, Bourliere M, Benhamou Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011;54(6):1114-22
   PubMed Web of Science ®Google Scholar
• F H, editor Pharmacokinetics, safety, and tolerability of faldarpevir in patients with different levels of renal impairment. 64th Annual Meeting of the American Association for the Study of Liver Diseases. November 1-5, Washington DC; 2013
   Google Scholar
• Joseph D. Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine/naloxone in subjects on stable addiction management therapy. 2013
   Google Scholar
• Sabo J. editor. Effect of multiple oral doses of faldaprevir on the multiple dose pharmacokinetics of a combination oral tablet of ethinylestradiol and levonorgestrel in healthy premenopausal female volunteers. The 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 1-5, Washington DC; 2013
   Google Scholar
• Rockstroh J. editor. STARTVerso 4 Phase iii trial of faldaprevir once-daily plus peg interferon α-2a and ribavirin (PR) in patients with HiV and HCV genotype-1 co-infection. 14th European AIDS Conference. October 16-19, Brussels, Belgium; 2013
   Google Scholar
• Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013;57(6):2143-54
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Bourliere M, Bronowicki JP, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013;57(6):2155-63
   PubMed Web of Science ®Google Scholar
• Dieterich D, Asselah T, Guyader D, et al. SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon alpha-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients. Antimicrob Agents Chemother 2014;58(6):3429-36
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013;369(7):630-9
   PubMed Web of Science ®Google Scholar
• Lalezari J, Holland L, Glutzer E, et al. editor. Rapid and consistent virologic responses in a phase 2 trial of a new all-oral combination of faldaprevir, deleobuvir, and PPI-668, with and without ribavirin, in patients with HCV genotype-1a infection. The 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 1-5, Washington DC; 2013
   Google Scholar
• Jensen D. editor. A pooled analysis of two randomized, double-blind placebo-controlled phase III trials (STARTVerso1 & 2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection. The 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-5; Washington DC; 2013
   Google Scholar
• Jacobsen I. STARTVerso3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. 64th Annual Meeting of the American Association for the Study of Liver Diseases. 1-5 November; Washinton DC; 2013
   Google Scholar